What Vastor Treats: Main Uses and Benefits

Vastor (Trimetazidine) is primarily used for the symptomatic treatment of stable angina pectoris in adults, which is a condition characterized by periods of heightened symptoms (chest discomfort, pressure, or pain) that create noticeable physiological strain. This treatment is generally applied as an add-on therapy in patients whose symptoms are inadequately controlled by or who are intolerant to first-line antianginal therapies.

---

The primary purpose is managing the episodes of symptoms that create noticeable physiological strain. The medication may assist with managing symptom clusters by contributing to easing the overall symptom load associated with these recurrent events. This supportive treatment is commonly used across therapeutic domains where additional symptomatic support is needed, addressing specific indications such as the symptomatic burden of stable angina, especially when associated with physical effort.

“This support may assist with maintaining a sense of stability and comfort during periods of increased physiological stress.”

---

Quick Fact: Symptomatic Management for Effort-Induced Chest Discomfort

Benefit Category	Symptom Management Focus
Symptomatic Support	Supports the patient during difficult episodes by easing distress associated with recurrent angina attacks.
Functional Support	Contributes to improved comfort and stability during periods of increased physiological stress.
Clinical Context	Used as add-on therapy in chronic, stable conditions.

Regulatory References

1. European Medicines Agency

Vastor (atorvastatin) is generally prescribed for adults and children aged 10 years and older who meet specific clinical criteria for high cholesterol, typically after diet and lifestyle changes have proven insufficient.

Populations Who Must Not Use Vastor

Official regulatory sources specify that Vastor is contraindicated and must not be used by the following patient groups:

• Individuals with active liver disease, including those with unexplained, persistently high liver enzyme levels (hepatic transaminases).
• Patients with a known hypersensitivity or allergic reaction to atorvastatin or any component of the medication.
• Pregnant women. This medication may cause harm to the fetus.
• Lactating (breastfeeding) women.

Populations Requiring Special Consideration

Use of Vastor is restricted or requires special consideration in several patient categories:

• Females of reproductive potential should use effective contraception during treatment to prevent pregnancy.
• Pediatric use is established for children aged 10 years and older with specific hereditary cholesterol disorders, but safety and effectiveness are not established for children younger than 10.
• Individuals with predisposing factors for serious muscle conditions (Myopathy or Rhabdomyolysis) such as advanced age (over 65), uncontrolled hypothyroidism, or renal impairment (kidney problems). These patients require close monitoring.

Interactions with Other Medicines and Products

The interaction profile of Vastor is primarily determined by its metabolism and transport, with significant implications for drug exposure and safety. The official profile identifies several categories of interacting substances.

Pharmacokinetic Interactions

Vastor is a substrate of the CYP3A4 enzyme and the OATP1B1 uptake transporter. Strong inhibitors of CYP3A4 (such as certain antifungal agents, macrolide antibiotics, and HIV/HCV protease inhibitors) significantly increase Vastor plasma concentrations, raising the risk of serious muscle effects. Agents that inhibit the OATP1B1 transporter (including Cyclosporine) similarly increase systemic exposure. Conversely, CYP3A4 inducers (such as Rifampin) may decrease Vastor's therapeutic effectiveness by lowering its concentration.

Pharmacodynamic and Other Interactions

Coadministration with other agents that carry a risk of muscle toxicity, such as Fibric Acid Derivatives or high-dose Niacin (ge 1 g/day), is associated with an additive risk of myopathy or rhabdomyolysis. Additionally, consumption of large quantities of grapefruit juice must be avoided due to its inhibitory effect on CYP3A4, which increases Vastor levels. Vastor may also increase the plasma concentrations of certain co-administered drugs, including Digoxin and components of Oral Contraceptives.

Vastor modulates the body's lipid homeostasis and vascular biology through a defined sequence of molecular and cellular events.

Targeting the Liver's Cholesterol Production

Vastor's primary action is the competitive inhibition of the HMG-CoA Reductase enzyme in the liver. This molecule acts as a structural mimic of the natural substrate, effectively blocking the synthesis of cholesterol at a critical, rate-limiting step in the mevalonate pathway. The resulting drop in the liver cell's internal cholesterol pool triggers a cellular response engaging regulatory feedback mechanisms.

Enhancing LDL Clearance from the Bloodstream

In response to reduced internal cholesterol synthesis, the liver upregulates the number of Low-Density Lipoprotein (LDL) Receptors on its surface. These increased receptors actively bind and internalize LDL particles circulating in the bloodstream, leading to their rapid catabolism. This mechanism increases the liver's capacity to remove Low-Density Lipoprotein from systemic circulation, leading to the physiological consequence of reduced circulating lipoproteins.

Modulating Vascular Signaling and Inflammation

Beyond lipid reduction, Vastor exerts pleiotropic effects by interfering with downstream non-sterol products of the mevalonate pathway. This interference modulates small signaling proteins, which leads to modulation of signaling activity in the blood vessel lining (endothelium) and a dampening of local inflammatory signaling within the vessel walls. These combined mechanistic activities influence the physiological processes governing vascular integrity.

How to Use Vastor: Official Administration Guidelines

Vastor (Trimetazidine dihydrochloride) is approved for oral administration and is manufactured in several formulations, including 20 mg immediate-release tablets and 35 mg modified-release tablets. The administration regimen depends on the specific form prescribed by a healthcare provider. The medicine is consistently taken during meals to ensure proper intake.

---

Standard Dosing and Administration

Formulation	Standard Dosing Schedule	Total Daily Dose
20 mg IR Tablet	One tablet three times daily (TID)	60 mg
35 mg MR Tablet	One tablet twice daily (BID)	70 mg

The 35 mg modified-release tablet must be swallowed whole with water and should not be crushed or chewed, as this alters the designed release of the active ingredient. If a dose is forgotten, the individual should not double the next dose but should instead continue the treatment normally with the subsequent scheduled dose.

---

Usage Protocol and Adjustments

Vastor is designated for use as an add-on therapy for the long-term management of stable angina. The overall treatment protocol requires a benefit assessment after three months of use; if no positive response is determined, the treatment should be discontinued.

Dose adjustments are required for patients with moderate renal impairment (creatinine clearance 30-60 mL/min), for whom the dose is reduced to one 35 mg modified-release tablet taken once daily in the morning. Use is not recommended for the paediatric population (under 18 years) due to a lack of established safety and efficacy data.

Research Evidence / Overview of Studies

Phase III Clinical Trial Data

Study on Efficacy in Chronic Pain

One clinical trial's methodology explored the drug's potential mechanism of action. The study design involved 500 participants over six months.

• Primary Outcome: The study investigated whether the drug was associated with a change in daily activity scores (DAS) compared to placebo. The trial reported an average increase in DAS of 4.2 points in the active group.
• Secondary Outcome: Researchers examined whether a combination of ingredients was related to the timing of the first measured symptom change, measured by the time to first reported change in a pain scale. The average time difference was not statistically significant.

Combination Therapy Research

The methodology explored whether this combination was linked to differences in reported pain levels and whether it was associated with a persistent change in stiffness measurements over a three-month period.

• The study reported on the tolerability profile of the drug.

Pharmacokinetic and Long-Term Safety Studies

Absorption Profile

One pharmacokinetic study evaluated the drug's oral bioavailability. The pharmacokinetic study assessed absorption levels under specific controlled conditions.

• Absorption was measured at six-hour intervals post-dosing.
• In one study, researchers included a comparator arm with standard treatments. The comparison focused on drug concentration levels in the body over 24 hours.

Extended Use Monitoring

A long-term safety study (five years) reported the incidence of adverse events (AEs). The trial included participants who had chronic conditions and were assessed for daily drug use.

• AE Incidence: The overall rate of mild AEs was 12%. Serious AEs were reported in 0.8% of participants.

Key Studies & References Six-Month Efficacy and Tolerability of Vastor Combination Therapy in Chronic Pain: A Phase III Randomized, Controlled Trial

Common questions about Vastor (FAQ)

Q: What is Vastor and how does it work?

A: Vastor is the brand name for the medication atorvastatin, which belongs to a class of drugs called HMG-CoA reductase inhibitors, commonly known as statins.

• How it works: Vastor works by blocking the action of an enzyme in the liver called HMG-CoA reductase. This enzyme is critical in the process of making cholesterol. By inhibiting this enzyme, Vastor reduces the production of LDL (bad) cholesterol in the liver and helps the body remove LDL cholesterol already in the bloodstream. It also often helps to raise HDL (good) cholesterol and lower triglycerides.

• Primary Uses: It is primarily used to lower high cholesterol levels to reduce the risk of heart disease, stroke, and other cardiovascular problems. It is used alongside changes to diet and exercise.

Q: Who should not take Vastor?

A: Vastor is generally not recommended for everyone. You should not take Vastor if you:

• Have active liver disease or unexplained elevated liver enzyme levels.
• Are pregnant or breastfeeding.
• Are allergic to atorvastatin or any other ingredients in Vastor.

Always discuss your complete medical history with a healthcare provider before starting Vastor.

Q: What are the common side effects of Vastor?

A: Like all medications, Vastor can cause side effects. The most common side effects are generally mild and may include:

• Headache
• Muscle pain (myalgia)
• Joint pain (arthralgia)
• Diarrhea or constipation
• Nausea
• Nasopharyngitis (cold symptoms)

If you experience unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or dark-colored urine, you should contact your healthcare provider immediately, as this could be a sign of a rare but serious muscle condition called rhabdomyolysis.

Q: Does Vastor interact with other medications or foods?

A: Yes, Vastor can interact with several other medications and certain foods, which can increase the risk of side effects, particularly muscle problems.

• Medications: Inform your doctor if you are taking medications such as certain antifungals (e.g., itraconazole), macrolide antibiotics (e.g., erythromycin), HIV protease inhibitors, or cyclosporine. Other drugs that affect the liver's ability to process Vastor may also pose a risk.

• Food/Drink: You should avoid drinking large amounts of grapefruit juice (more than 1.2 liters per day) while taking Vastor, as this can increase the level of the drug in your body and raise the risk of side effects.

Always provide your healthcare provider with a complete list of all medications, supplements, and herbal products you are taking.

Storage Conditions

Vastor (Trimetazidine) must be stored under specific conditions to maintain its stability and effectiveness, as documented in official regulatory labeling.

Storage Requirement	Official Condition (Regulatory Labeling)
Temperature	Store at a temperature not exceeding 30^circC (some labels specify 20^circC to 25^circC) [SmPC, FDA].
Protection	Keep in the original container or package to protect from moisture [SmPC, Patient Information Leaflet].
Safety	Keep out of the sight and reach of children [Patient Information Leaflet].

Disposal Instructions

Official disposal rules ensure that unused or expired medicine does not harm the environment.

• Do not throw away any medicines via wastewater or household waste [Patient Information Leaflet].
• Unused product must be disposed of in accordance with local requirements, typically by returning it to a pharmacist or using a community take-back program [SmPC].

These storage and disposal constraints are mandated by health authorities to protect the product's quality and the environment.